IL2 and colonic neoplasm: The authors showed that the newly engineered IL-2 caused reduced expansion of immunosuppressive T cells (Treg) in comparison to native IL-2 and led to a dose-dependent delay in tumor growth, both in colon cancer and melanoma mouse models, without immunogenicity and with reduced toxicity [99].